This article has been updated from a previous version to include BioSystems International's complete name.
NEW YORK, Feb. 23 (GenomeWeb News) - BioSystems International and AstraZeneca will collaborate to discover biomarkers for the treatment of osteoarthritis, BioSystems International announced today.
Under the agreement, AstraZeneca will provide samples and funding for the research done by BSI, which will retain rights and income from diagnostic applications.
AstraZeneca receives a non-exclusive license to use the results for internal R&D activities, including exclusive rights to any new targets. The drug maker will also have a worldwide license to cite or recommend the use of the products developed by BSI as part of the collaboration.
Financial details were not released.